Publications by authors named "A T Billeter"
ASO Visual Abstract: Defining and Predicting Early Recurrence for Optimal Treatment Strategies in Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer--An International Multicenter Study.
Joseph R Habib Ammar A Javed Ingmar F Rompen Camila Hidalgo Salinas Anthony Sorrentino Adrian T Billeter
Ann Surg Oncol
January 2025
Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study.
Joseph R Habib Ammar A Javed Ingmar F Rompen Camila Hidalgo Salinas Anthony Sorrentino Adrian T Billeter
Ann Surg Oncol
December 2024
Article Synopsis
- This study investigates early recurrence in patients with pancreatic ductal adenocarcinoma (PDAC) derived from intraductal papillary mucinous neoplasm (IPMN), aiming to identify predictors to help guide patient management.
- The research found that early recurrence is defined as occurring within 10.5 months post-surgery, affecting 38% of patients who experienced recurrence, with CA19-9 levels and N2 disease being significant predictors.
- Adjuvant chemotherapy showed a survival advantage only for high-risk patients, highlighting the importance of risk stratification for better treatment outcomes.
Metabolic syndrome (MetS) presents a global health challenge characterized by cardiometabolic risk factors like central obesity, elevated blood pressure, dyslipidemia, and high fasting glucose levels. Despite lifestyle interventions and medications, the increasing prevalence of MetS calls for effective treatments. Sleeve gastrectomy (SG) has emerged as a promising intervention.
View Article and Find Full Text PDFArticle Synopsis
- Liver fibrosis results from chronic liver inflammation leading to excess extracellular-matrix production by activated hepatic stellate cells (HSCs), which can lead to serious liver damage.* -
- Research on mice showed that lacking HIF-prolyl-hydroxylase 1 (PHD1) reduced liver fibrosis severity and related inflammation, while treatment with the inhibitor DMOG did not prevent fibrosis.* -
- PHD1 deficiency was linked to decreased activation of HSCs and lower expression of fibrotic and inflammatory markers, suggesting that targeted PHD1 inhibitors might be effective in managing liver fibrosis.*